Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference

GlobeNewswire

02/24

NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the TD Cowen 46^th Annual Health Care Conference in Boston. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Tuesday, March 3, 2026 at 1:50 pm EST and will host one-on-one meetings with investors.

A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2613719397"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613719397\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613719397?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613719397","market":"us","top_or_hot":-1,"title":"Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference","media":"GlobeNewswire","content":"<html><body><p>NEW YORK and WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Dianthus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the TD Cowen 46<sup>th</sup> Annual Health Care Conference in Boston. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Tuesday, March 3, 2026 at 1:50 pm EST and will host one-on-one meetings with investors.</p> <p>A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.</p> <p><strong>About Dianthus Therapeutics</strong><br/>Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.</p> <p>To learn more, please visit www.dianthustx.com and follow us on LinkedIn. </p> <p><strong>Contact </strong><br/>Jennifer Davis Ruff<br/>Dianthus Therapeutics<br/>jdavisruff@dianthustx.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/OGIyYjQ5YzQtNTgyMS00N2VkLWFkOGMtNmZmNWVhMGQ5NGY4LTEyNzE5MzktMjAyNi0wMi0yNC1lbg==/tiny/Dianthus-Therapeutics-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2026-02-24 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>NEW YORK and WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Dianthus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the TD Cowen 46<sup>th</sup> Annual Health Care Conference in Boston. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Tuesday, March 3, 2026 at 1:50 pm EST and will host one-on-one meetings with investors.</p> <p>A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.</p> <p><strong>About Dianthus Therapeutics</strong><br/>Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.</p> <p>To learn more, please visit www.dianthustx.com and follow us on LinkedIn. </p> <p><strong>Contact </strong><br/>Jennifer Davis Ruff<br/>Dianthus Therapeutics<br/>jdavisruff@dianthustx.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/OGIyYjQ5YzQtNTgyMS00N2VkLWFkOGMtNmZmNWVhMGQ5NGY4LTEyNzE5MzktMjAyNi0wMi0yNC1lbg==/tiny/Dianthus-Therapeutics-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XLV","symbol_name":"健康照护类股ETF-SPDR","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243371/0/en/Dianthus-Therapeutics-to-Participate-in-The-TD-Cowen-46th-Annual-Health-Care-Conference.html","article_id":"2613719397","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613719397","pubTimestamp":1771934400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"NEW YORK and WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","BK4207":"综合性银行","BK4007":"制药","BK4566":"资本集团","TD":"道明银行","BK4588":"碎股","BK4539":"次新股","BK4585":"ETF&股票定投概念","XBI":"SPDR S&P Biotech ETF","COWN":"高宏集团","BK4139":"生物科技","BK4581":"高盛持仓","LENZ":"Therapeutics","BK4127":"投资银行业与经纪业","LABU":"三倍做多标普生物-Direxion"},"translate_title":"Dianthus Therapeutics将参加TD Cowen第46届年度医疗保健会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TD":1.5,"XBI":0.6,"COWN":1.5,"LABU":0.6,"XLV":1.5,"LENZ":1.5},"content_text":"NEW YORK and WALTHAM, Mass., Feb.  24, 2026  (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the TD Cowen 46th Annual Health Care Conference in Boston. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Tuesday, March 3, 2026 at 1:50 pm EST and will host one-on-one meetings with investors. A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases. To learn more, please visit www.dianthustx.com and follow us on LinkedIn.  Contact Jennifer Davis RuffDianthus Therapeuticsjdavisruff@dianthustx.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}